Mizuho Medy Co (TSE:4595) Research & Development: 円0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4595 Mizuho Medy Co Ltd TSE:4595
84 GF Score
Price 円1,662.00
GF Value 円1,440.52
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Mizuho Medy Co Research & Development?

Mizuho Medy Co TSE:4595 +0.12% 84 Research & Development is 円0 Mil as of Dec. 2025. GuruFocus rates TSE:4595 with a GF Score™ of 84/100 and a GF Value™ of 円1,440.52 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Mizuho Medy Co's Research & Development for the three months ended in Dec. 2025 was 円0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was 円0 Mil.

Mizuho Medy Co  (TSE:4595) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Mizuho Medy Co Research & Development Related Terms

Mizuho Medy Co Research & Development Historical Data

* Premium members only.

The historical data trend for Mizuho Medy Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mizuho Medy Co Research & Development Chart

Mizuho Medy Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 592.32 605.47 669.00 783.00 819.00

Mizuho Medy Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4595
84GF Score
Mizuho Medy Co Ltd TSE:4595
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mizuho Medy Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円0 Mil mean?
Mizuho Medy Co (TSE:4595) has a Research & Development of 円0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Mizuho Medy Co and its competitors.
Is Mizuho Medy Co's Research & Development too high?
Mizuho Medy Co's current Research & Development is 円0 Mil. Overall, Mizuho Medy Co has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's Research & Development compare to ZTS and UTHR?
Mizuho Medy Co's Research & Development of 円0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Mizuho Medy Co and its competitors. Mizuho Medy Co's current Research & Development is 円0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,440.52, compared to a current price of 円1,662.00 — trading 15.4% above its estimated fair value. The current Research & Development is 円0 Mil. Mizuho Medy Co's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current Research & Development is 円0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?

Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued. The current stock price of 円1,662.00 is trading 15.4% above its estimated GF Value™ of 円1,440.52. GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.

Key valuation signals for TSE:4595:

  • Research & Development: 円0 Mil
  • GF Value™: 円1,440.52 vs. price of 円1,662.00 (15.4% above fair value)
  • GF Score™: 84/100 with 3 warning signs

No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mizuho Medy Co Business Description

Address 5-4 Fujinoki-machi, Saga Prefecture, Tosu, JPN, 841-0048
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
84GF Score

Get the complete analysis for TSE:4595

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,662.00
Price
円1,440.52
GF Value